DOI: 10.1055/s-00034923

Adipositas - Ursachen, Folgeerkrankungen, Therapie

LinksClose Window

References

Novo Nordisk.
Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes.
2017 [Available from: http://press.novonordisk- us.com/2017–12–5-Novo-Nordisk-Receives-FDAApproval-of-OZEMPIC-R-semaglutide-InjectionFor-the-Treatment-of-Adults-with-Type-2-Diabetes. Zugegriffen: Jan 08 2018..

Download Bibliographical Data

Access:

We do not assume any responsibility for the contents of the web pages of other providers.